Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
October 2016
-
Media ReleaseNovartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow upLatest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year…
-
Media ReleaseNovartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of careLEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups…
-
Media ReleaseNovartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global surveyGlobal survey of over 8,300 patients shows over half have not achieved clear skin (57%), with the majority taking the historical standard of care treatment[1]* Majority (84%) face…
-
Media ReleaseNovartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patientsCosentyx® delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years[1] New data show…
September 2016
-
Media ReleaseNovartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraineARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo…
-
Media ReleaseSandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challengesDespite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need Sandoz "HACk" - Healthcare Access Challenge - is…
-
Media ReleaseNovartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditionsIlaris® (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease These three simultaneous approvals conducted under FDA…
-
Media ReleaseNovartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patientsIn a Phase III clinical study, Zykadia® extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global…
-
Media ReleaseNovel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugsResults published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites…
-
Media ReleaseImportant new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patientsNew analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
-
Media ReleaseNovartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patientsEXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary…
-
Media ReleaseNew Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 yearsACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya® (fingolimod) had significantly lower disability progression compared to those…
Pagination
- ‹ Previous page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- …
- 88
- › Next page